Submit your claim details for a free, no obligation case review.
Get Started:
So far, any attempt for an effective traumatic brain injury (TBI) drug has failed. Pharmos said that its experimental drug dexanabinol, while only partially preventing cognitive problems in patients undergoing heart surgery in a midstage study, is hoping it will succeed in a larger, more important, phase III study expected to be completed before the end of the year.
The high-risk described phase III study is designed to determine if dexanabinol can protect accident victims at risk for traumatic brain injury. The phase III study involves more than 800 patients who are at risk of moderate to traumatic brain damage resulting from accidents. Dexanabinol is a drug synthesized from cannabinoid compounds – a chemical cousin of marijuana.
Some analysts believe the commercial market for a TBI drug is potentially more than $1 billion, but still, relatively very little is known about brain injuries. Depending on the results of the phase III study, it could lead to dexanabinol being filed with the FDA, which investors anxiously await.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.